Rebound thrombosis within 24 hours after interruption of therapy with rivaroxaban

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg et al. · New England Journal of Medicine · 2011 · 9.4K citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design

Hugh Calkins, Riccardo Cappato, Josép Brugada et al. · Heart Rhythm · 2012 · 1.5K citations · Full text

Medicine, Cardiology, Surgery +17

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor

Elisabeth Perzborn, Andreas Wilmen, Jens Pohlmann et al. · Journal of Thrombosis and Haemostasis · 2005 · 584 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation

Riccardo Cappato, Francis E. Marchlinski, Stefan H. Hohnloser et al. · European Heart Journal · 2015 · 427 citations · Full text

Medicine, Cardiology, Pharmacology +12

Radiofrequency Catheter Ablation of Atrial Fibrillation: A Cause of Silent Thromboembolism?

Fiorenzo Gaïta, Domenico Caponi, Martina Pianelli et al. · Circulation · 2010 · 358 citations · Full text

Medicine, Cardiology, Surgery +17